Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Leflunomide as Primary Prophylaxis Against Cytomegalovirus (CMV) Reactivation in Haploidentical Haematopoietic Stem Cell Transplant (HIT) - Single, Arm, Phase 2 Clinical Trial

NCT07709013 is registered in ClinicalTrials.gov with Tata Memorial Centre as lead sponsor.

NCT NCT07709013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07709013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Leflunomide as Primary Prophylaxis Against Cytomegalovirus (CMV) Reactivation in Haploidentical Haematopoietic Stem Cell Transplant (HIT) - Single, Arm, Phase 2 Clinical Trial
Lead sponsor
Tata Memorial Centre
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2024
Completion date
April 30, 2029
Enrollment
22 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies